期刊文献+

胃癌晚期靶向治疗研究进展

Advances in Targeted Therapy for Advanced Gastric Cancer
下载PDF
导出
摘要 随着医疗技术研究的深入,人们对抗体结构及功能有了更深入的认识,靶向消除或抑制肿瘤细胞生长的治疗技术正已为抗肿瘤的研究方向。目前,被批准在临床应用的靶向药物已有20多种,其主要通过靶向阻断肿瘤细胞的血供和细胞信号通路,进而达到杀死肿瘤细胞的作用;在胃癌晚期患者中应用靶向治疗,能够准确作用于肿瘤病灶,阻断肿瘤细胞的分裂和增殖,提高治疗效果。 With the in-depth study of medical technology, people have a deeper understanding of the structure and function of antibody, To eliminate or inhibit the growth of tumor cells in the treatment of cancer is the direction of research. At present, there are more than 20 kinds of targeted drugs approved in clinical applications, mainly through the target to block the blood supply of tumor cells and cell signaling pathway, and then to kill the role of tumor cells. Targeted therapy in patients with advanced gastric cancer can be used in the treatment of tumor lesions, blocking tumor cell division and proliferation, and improve the treatment effect.
出处 《中国继续医学教育》 2016年第20期121-122,共2页 China Continuing Medical Education
关键词 胃癌晚期 靶向治疗 肿瘤干细胞 抗体 Advanced gastric cancer, Targeted therapy, Tumor stem cells,Antibody
  • 相关文献

参考文献9

二级参考文献82

  • 1Lucas Faria Abraho-Machado,Alexandre Andrade dos Anjos Jácome,Durval Renato Wohnrath,José Sebastio dos Santos,Estela Cristina Carneseca,José Humberto Tavares Guerreiro Fregnani,Cristovam Scapulatempo-Neto.HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays[J].World Journal of Gastroenterology,2013,19(38):6438-6446. 被引量:13
  • 2郑航,陈锦章,廖旺军,罗荣城.贝伐单抗联合伊立替康治疗转移性结直肠癌的近期疗效观察[J].南方医科大学学报,2006,26(5):689-691. 被引量:12
  • 3张力,王志强.大肠癌靶向治疗进展[J].中国癌症杂志,2007,17(1):18-23. 被引量:19
  • 4Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000:Cancer Incidence, Mortality and Prevalence Worldwide [R],Version 1.0. IARC Cancer Base No. 5. Lyon: IARC 2001.
  • 5Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase Ⅱ ,randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer[J]. J Clin Oncol. 2003,21:60-65.
  • 6Kabbinavar F, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase Ⅱ trial[J]. J Clin Oncol. 2005,23:3697-3705.
  • 7Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med. 2004,350:2335-2342.
  • 8Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-study(ahst) [J]. Proc Am Soc Clin Oncol. 2006,24:18s.
  • 9Giantonio BJ, Catalano PJ, Meropol, NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study 3200 [J]. J Clin Oncol. 2005,23:1s.
  • 10Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase Ⅲ study in patients with previously treated metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM2) (abst) [J]. Proc Am Soc Clin Oncol,2006,24: 18s.

共引文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部